What Ustar does

Ustar is a Hangzhou-based molecular diagnostics company founded in 2005 that develops and manufactures point-of-care (POCT) nucleic-acid testing platforms for infectious disease, public health, and agricultural applications. Its portfolio is organized around three product families — EasyNAT, MultNAT, and PortNAT — built on a proprietary vitrification-based reagent preservation chemistry and a closed-tube, integrated POCT architecture that allows room-temperature shipment and operation outside centralized laboratory infrastructure. The company maintains a 5,000 sqm GMP manufacturing facility, an R&D team of more than 150 people (approximately 32% of total headcount, with over half holding master's-level qualifications), and a portfolio of 62 granted patents with 90+ applications pending.

The company sells instruments and proprietary single-use consumables to clinical laboratories, hospitals, public-health agencies, and agricultural testing programs in China and overseas. Commercial reach covers more than 3,000 domestic medical institutions and export distribution to 90+ countries, with regulatory clearances spanning NMPA Class III, CE IVDR, FDA, WHO Emergency Use Listing (EUL, including for monkeypox assays granted in May 2025), ANVISA, TGA, and HSA. Ustar has also been included in the first batch of the UN International Public Procurement catalog, giving it direct access to multilateral public-health procurement.

Revenue mechanics are anchored in an installed-instrument/razor-blade model: instruments are placed at customer sites, and recurring revenue is generated through proprietary closed-tube consumable cartridges whose chemistry is locked to Ustar's reagents. Customer segments are diversified across Chinese hospitals and CDC channels, international public-health tenders, and agricultural testing programs; the company is privately held and has disclosed one institutional funding round of approximately $47.1 million in November 2021 led by CPE with co-lead Oriental Fortune Capital. No revenue, ARR, or unit-shipment figures have been disclosed.

Name

Ustar

Legal name

杭州优思达生物技术股份有限公司

Website

https://bioustar.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Ustar is a Hangzhou-based molecular diagnostics company (founded 2005) that develops closed-tube POCT nucleic-acid testing platforms (EasyNAT, MultNAT, PortNAT) using proprietary room-temperature reagent chemistry, serving hospitals, public-health agencies, and agricultural testing programs across China and 90+ export markets.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics (POCT In Vitro Diagnostics)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Molecular diagnostics
• Point-of-care testing
• Infectious disease testing
• Nucleic acid detection
• Tuberculosis diagnostics

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Molecular Diagnostic Instruments and Reagents: Sale of molecular POCT diagnostic systems (EasyNAT, MultNAT, PortNAT) and associated diagnostic reagents covering infectious disease testing (respiratory, tuberculosis, tropical diseases, gastrointestinal, reproductive health, antimicrobial resistance, oncology), animal health diagnostics, and agricultural applications. The company operates through direct sales channels domestically and international sales channels, with revenue generated from device sales, reagent sales, and consumables. GMP-certified manufacturing facilities with fully automated production lines and ISO13485:2016 quality management system certification.
2. Technical and After-Sales Services: Technical support services provided to customers including after-sales service, product training, and clinical monitoring support for IVD products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Ustar develops, manufactures, and sells point-of-care molecular diagnostic (POCT) instruments and nucleic acid detection reagent kits for infectious diseases, tuberculosis, respiratory infections, reproductive health, antimicrobial resistance, tropical diseases, and agricultural/livestock applications. The company offers three proprietary instrument platforms — EasyNAT (rapid single-target detection, 25-minute TAT), MultNAT (high-throughput multi-pathogen panels up to 30+ in one tube), and PortNAT (135g portable self-testing with 15-minute TAT) — each supported by an extensive certified reagent menu and disposable consumables. All products use an integrated closed-tube architecture that performs nucleic acid extraction, amplification, and detection in a single sealed cartridge, eliminating the need for traditional PCR laboratory infrastructure.

Product overview

Ustar (杭州优思达生物技术股份有限公司) is a molecular POCT diagnostics company founded in 2005, specializing in innovative point-of-care molecular diagnostic technology. The product portfolio consists of three core instrument platforms: EasyNAT (rapid single-target detection system with 4/8/16 channels), MultNAT (high-throughput multi-panel detection system with 16/32 channels supporting up to 30+ pathogens), and PortNAT (portable self-testing device for non-professional use). These platforms are supported by comprehensive reagent kits covering respiratory infections, tuberculosis, gastrointestinal diseases, tropical diseases, sexually transmitted infections, antimicrobial resistance monitoring, reproductive health, and veterinary applications. The company also offers disposable consumables including nucleic acid detection devices and test strips. All three systems use proprietary fully-enclosed cartridge technology integrating sample lysis, nucleic acid extraction, amplification and detection in a single tube.

Differentiator

Problem solved

Functional benefit

Brands

• EasyNAT: 核酸快速检测系统，快速精准，高效筛查，提供呼吸道、结核、生殖健康等多系列检测试剂。
• MultNAT
• PortNAT

Products and services

• EasyNAT Nucleic Acid Rapid Detection System Automated molecular POCT instrument platform for rapid single-target nucleic acid detection with 4/8/16 channels. Provides fastest 25-minute reporting with only 1 minute of manual operation; CE-marked and NMPA Class III certified. Designed for clinical professionals across hospital departments including fever clinics, emergency, pediatrics, and respiratory medicine.
• MultNAT Multi-Panel Nucleic Acid Detection System High-throughput real-time quantitative PCR instrument with 10-color fluorescence and high-resolution melting curve technology. Supports single-pathogen to 30+ pathogen panels in 16/32 channels for high-throughput screening. CE-marked and NMPA Class III certified. Designed for clinical laboratories and hospital departments requiring multiplex molecular testing for respiratory, gastrointestinal, meningitis, tropical disease, and tuberculosis panels.
• PortNAT Portable Nucleic Acid Self-Testing System Compact portable nucleic acid detection platform weighing 135g, designed for non-professional users with <2 minutes of manual operation. Battery-powered, smartphone-sized device with 15-minute detection time using proprietary Cross-Priming Amplification technology. Three-color LED result display with reusable base and disposable detection tubes. Designed for primary healthcare, field, home, and non-laboratory settings.
• EasyNAT Reagent Kits Comprehensive menu of NMPA Class III certified reagent kits for the EasyNAT system covering respiratory infections (Mycoplasma pneumoniae, influenza A/B, RSV, COVID-19, pertussis, adenovirus, rhinovirus, Legionella, etc.), tuberculosis (MTB/NTM, MTB complex), and reproductive health (CT/NG, Mycoplasma genitalium, Ureaplasma, GBS, HSV-1/2). 14 CE/IVD certified kits with 10+ in registration.
• MultNAT Reagent Kits Multi-panel syndromic testing reagents for the MultNAT system covering respiratory panels (24-plex), gastrointestinal panels (24-plex), fungal panels (18-plex), tropical disease panels (14-plex), meningitis panels (20-plex), tuberculosis (MTB/RIF with 99.38% concordance), antimicrobial resistance (carbapenem resistance, MRSA), sexually transmitted infections (HPV, HIV-1 VL, mpox), and livestock (16-plex bovine mastitis, African Swine Fever).
• PortNAT Reagent Kits Point-of-care testing reagents for the PortNAT portable system including tuberculosis (tongue swab non-sputum TB detection), monkeypox virus (first Chinese WHO EUL certified MPXV assay), and citrus greening disease (HLB) detection kits for agricultural field testing.
• Disposable Nucleic Acid Detection Device Single-use sealed nucleic acid detection cartridge using lateral flow double-antibody sandwich method. Features independent sealing to prevent aerosol contamination. Designed as a consumable for Ustar's molecular POCT platforms.
• Disposable Nucleic Acid Test Strips Lateral flow-based rapid detection strips for direct detection of nucleic acid amplification products. Simple operation and rapid interpretation, designed for use with Ustar's molecular POCT systems.

Quantifiable outcome

• MultNAT MTB/RIF: MTB detection total coincidence rate 99.38%, Rifampicin resistance coincidence rate 100% — validated against Xpert MTB/RIF Ultra
• +8 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core.

• University of Indonesia (印度尼西亚大学)coreStrategic or Co-development Partner · 15 August 2025Ustar signed a Memorandum of Understanding (MoU) with University of Indonesia in Jakarta on August 15, 2025. The partnership establishes a Joint Innovation Center for Molecular POCT diagnostic technology, focusing on: (1) Joint R&D of molecular POCT diagnostic technology; (2) Development and clinical validation of products for tropical diseases including dengue fever and malaria; (3) Technology transfer and local production in Indonesia; (4) Talent development and capacity building; (5) Establishment of Indonesia National Molecular Diagnostic Laboratory Surveillance Network. The University, founded in 1849, is Indonesia's oldest higher education institution and a world-leading research university.
• Stop TB PartnershipcoreStrategic or Co-development PartnerStop TB Partnership supported Ustar's TB innovation projects for global clinical trials, validating the company's TB diagnostic products in resource-limited settings and contributing to global TB elimination efforts.
• Chinese Academy of Medical Sciences — Institute of Pathogenic Biology (中国医学科学院病原生物学研究所)coreStrategic or Co-development PartnerEstablished a joint laboratory with the Chinese Academy of Medical Sciences Institute of Pathogenic Biology for developing portable rapid detection platforms for high-pathogenicity pathogens. Also collaborated on joint development of dengue, Zika, and Chikungunya virus nucleic acid detection reagents with Zhejiang CDC.
• China Anti-tuberculosis Association (中国防痨协会)coreStrategic or Co-development PartnerUstar has been designated as a TB Medical Transformation Innovation Base by the China Anti-tuberculosis Association, facilitating the transfer and commercialization of TB diagnostic innovations from research to clinical application.
• Zhejiang Provincial CDC (浙江省疾控中心)coreStrategic or Co-development PartnerJoint development with Zhejiang CDC for dengue, Zika, and Chikungunya virus nucleic acid detection reagents, demonstrating collaboration in disease surveillance and diagnostic product development for tropical diseases.
• Multiple Chinese Hospitals (Research/Clinical Collaborations)coreStrategic or Co-development PartnerCollaborative product development with over a dozen leading Chinese hospitals including: Shanghai Jiao Tong University School of Medicine Renji Hospital (systemic lupus erythematosus gene testing); Shanghai Children's Hospital (diarrheal pathogen multiplex detection); Shanghai First People's Hospital (urinary tract infection pathogen detection); Huadong Hospital affiliated to Fudan University (herpesvirus multiplex detection); Jiangsu Provincial People's Hospital (C. difficile testing); Nanjing Children's Hospital (Strep A and GC testing); Children's Hospital of Zhejiang University School of Medicine (meningitis pathogen multiplex detection); Henan Children's Hospital (enterovirus multiplex detection); Zhengzhou University Third Affiliated Hospital (folate metabolism gene polymorphism testing); Baoding Children's Hospital (Mycoplasma pneumoniae drug resistance gene testing).
• National Naval Orange Engineering Research Center (国家脐橙工程技术研究中心)coreStrategic or Co-development PartnerJoint development with the National Naval Orange Engineering Research Center for the PortNAT Citrus Greening Disease (HLB) nucleic acid rapid detection system — a portable field testing solution for citrus orchards that has been deployed at multiple fruit industry groups.
• National Health Commission / Ministry of Science and Technology (China)coreStrategic or Co-development PartnerWith support from the Ministry of Science and Technology and WHO, Ustar successfully developed diagnostic solutions for major infectious diseases including tuberculosis, malaria, COVID-19, mpox, dengue fever, Zika virus, and Chikungunya fever. The company also hosted foreign health officials and scholars for training visits under the Health Commission's foreign aid medical training program.

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Cepheid (Danaher): Cepheid's GeneXpert is the dominant molecular POCT platform, particularly the Xpert MTB/RIF Ultra for tuberculosis — Ustar's flagship MultNAT MTB/RIF was validated head-to-head against this benchmark with >99% concordance, making Cepheid its most direct global competitor.
• bioMérieux (BioFire): BioFire FilmArray syndromic panels (respiratory, GI, meningitis, pneumonia) directly compete with Ustar's MultNAT multiplex panels across similar clinical use cases and customer segments in hospital laboratories.
• QIAGEN: QIAstat-Dx is a direct molecular POCT competitor with multiplex syndromic panels, targeting the same decentralized hospital and clinical lab customers as Ustar's MultNAT system.
• Sansure Biotech: Sansure is a leading Chinese molecular diagnostics company offering PCR-based infectious disease kits and automated extraction systems, competing head-on with Ustar in the Chinese hospital and CDC market.
• Daan Gene: Daan Gene is a major Chinese molecular diagnostics manufacturer with a broad infectious disease PCR reagent portfolio and automated instrumentation, directly competing with Ustar for Chinese hospital and public-health contracts.
• Molbio Diagnostics: Molbio's Truenat is a portable, battery-operated molecular POCT platform widely deployed for TB and infectious disease in resource-limited settings, making it a direct comparable to Ustar's PortNAT in global donor-funded markets.
• Tianlong Science and Technology: Tianlong is a Chinese molecular diagnostics company producing nucleic acid extraction systems, real-time PCR instruments, and reagent kits that compete directly with Ustar's EasyNAT and MultNAT product lines in domestic and emerging markets.
• Autobio Diagnostics: Autobio is a major Chinese in vitro diagnostics company with a growing molecular diagnostics business, providing similar infectious disease PCR reagents and automated instruments targeting the same Chinese hospital networks as Ustar.

Broad incumbents

• Abbott: Abbott's ID NOW and m2000 RealTime systems are broad-incumbent molecular diagnostics platforms spanning POCT and central-lab testing, with overlapping respiratory and infectious disease menus serving similar hospital and primary-care customers as Ustar.
• Hologic: Hologic's Panther system is a high-throughput molecular diagnostics platform with overlapping infectious disease and STI menu, competing for the same hospital laboratory customers as Ustar's MultNAT multiplex system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ustar